TR200102880T2 - Enjekte edilebilir naltrekson mikrokre bileçimleri ve bunlarìn eroin ve alkol tketiminin azaltìmì i‡in kullanìmì - Google Patents

Enjekte edilebilir naltrekson mikrokre bileçimleri ve bunlarìn eroin ve alkol tketiminin azaltìmì i‡in kullanìmì

Info

Publication number
TR200102880T2
TR200102880T2 TR2001/02880T TR200102880T TR200102880T2 TR 200102880 T2 TR200102880 T2 TR 200102880T2 TR 2001/02880 T TR2001/02880 T TR 2001/02880T TR 200102880 T TR200102880 T TR 200102880T TR 200102880 T2 TR200102880 T2 TR 200102880T2
Authority
TR
Turkey
Prior art keywords
heroin
microcirculation
reduction
alcohol consumption
injectable
Prior art date
Application number
TR2001/02880T
Other languages
English (en)
Inventor
R. Tice Thomas
K. Staas Jay
M. Ferrell Teresa
Original Assignee
Southern Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Research Institute filed Critical Southern Research Institute
Publication of TR200102880T2 publication Critical patent/TR200102880T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Abstract

Bir poli(D,L-laktid) matris içinde naltrekson ve küçük bir miktar etil asetat bakiyesi içeren enjekte edilebilir, yavaç bir çekilde sal nmaktad r. Bu bileçim eroin ve alkol baG ml lar nda, baG ml l k yaratan maddenin tüketiminin azalt lmas nda kullan lmaktad r.
TR2001/02880T 1999-04-09 2000-04-08 Enjekte edilebilir naltrekson mikrokre bileçimleri ve bunlarìn eroin ve alkol tketiminin azaltìmì i‡in kullanìmì TR200102880T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12847799P 1999-04-09 1999-04-09

Publications (1)

Publication Number Publication Date
TR200102880T2 true TR200102880T2 (tr) 2002-03-21

Family

ID=22435553

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02880T TR200102880T2 (tr) 1999-04-09 2000-04-08 Enjekte edilebilir naltrekson mikrokre bileçimleri ve bunlarìn eroin ve alkol tketiminin azaltìmì i‡in kullanìmì

Country Status (25)

Country Link
US (1) US6306425B1 (tr)
EP (1) EP1171132B1 (tr)
JP (2) JP4995371B2 (tr)
KR (1) KR100621261B1 (tr)
CN (1) CN1210031C (tr)
AT (1) ATE262906T1 (tr)
AU (1) AU780852B2 (tr)
BR (1) BR0009639A (tr)
CA (1) CA2369302C (tr)
CZ (1) CZ20013636A3 (tr)
DE (1) DE60009477T2 (tr)
DK (1) DK1171132T3 (tr)
EA (1) EA004734B1 (tr)
ES (1) ES2218147T3 (tr)
HK (1) HK1047245B (tr)
HU (1) HUP0200838A3 (tr)
IL (2) IL145802A0 (tr)
MX (1) MXPA01010185A (tr)
NO (1) NO328647B1 (tr)
NZ (1) NZ515359A (tr)
PL (1) PL196930B1 (tr)
PT (1) PT1171132E (tr)
TR (1) TR200102880T2 (tr)
UA (1) UA79921C2 (tr)
WO (1) WO2000061147A1 (tr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US7919119B2 (en) 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
AU2001223396A1 (en) * 2000-02-01 2001-08-14 Disetronic Licensing Ag Container and device for administering a substance
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
ES2292775T3 (es) 2001-07-06 2008-03-16 Penwest Pharmaceuticals Co. Formulaciones de liberacion prolongada de oximorfona.
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
WO2003004032A1 (en) 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US7041320B1 (en) 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
US7157102B1 (en) 2002-05-31 2007-01-02 Biotek, Inc. Multi-layered microcapsules and method of preparing same
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
US7842377B2 (en) * 2003-08-08 2010-11-30 Boston Scientific Scimed, Inc. Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US20040109886A1 (en) * 2002-08-27 2004-06-10 Larry Rigby Methods and apparatus for transdermal delivery of abusable drugs with a deterrent agent
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US7883490B2 (en) 2002-10-23 2011-02-08 Boston Scientific Scimed, Inc. Mixing and delivery of therapeutic compositions
WO2004082459A2 (en) * 2003-03-13 2004-09-30 Burgess Cheryl M Methods of administering a material into a patient for dermal enhancement
WO2004108084A2 (en) * 2003-06-04 2004-12-16 Alkermes Controlled Therapeutics, Ii Polymorphic forms of naltrexone
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US20050031713A1 (en) * 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP3A4 sensitive patients
US7976823B2 (en) 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
CA2533887A1 (en) * 2003-09-30 2005-04-14 Acusphere, Inc. Injectable, oral, or topical sustained release pharmaceutical formulations
US7901770B2 (en) 2003-11-04 2011-03-08 Boston Scientific Scimed, Inc. Embolic compositions
EP1718258B1 (en) * 2004-02-23 2009-03-25 Euro-Celtique S.A. Abuse resistance opioid transdermal delivery device
US7736671B2 (en) 2004-03-02 2010-06-15 Boston Scientific Scimed, Inc. Embolization
US20050245461A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
US8173176B2 (en) 2004-03-30 2012-05-08 Boston Scientific Scimed, Inc. Embolization
US7919499B2 (en) 2004-04-22 2011-04-05 Alkermes, Inc. Naltrexone long acting formulations and methods of use
US7311861B2 (en) 2004-06-01 2007-12-25 Boston Scientific Scimed, Inc. Embolization
US7858183B2 (en) 2005-03-02 2010-12-28 Boston Scientific Scimed, Inc. Particles
US7727555B2 (en) 2005-03-02 2010-06-01 Boston Scientific Scimed, Inc. Particles
US7963287B2 (en) 2005-04-28 2011-06-21 Boston Scientific Scimed, Inc. Tissue-treatment methods
CN1872063B (zh) * 2005-06-03 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 纳美芬或其盐的长效注射用微球或组合物及其制备方法
US9463426B2 (en) 2005-06-24 2016-10-11 Boston Scientific Scimed, Inc. Methods and systems for coating particles
US7947368B2 (en) 2005-12-21 2011-05-24 Boston Scientific Scimed, Inc. Block copolymer particles
EP1810714A1 (de) * 2006-01-19 2007-07-25 Holger Lars Hermann Verwendung einer Kombination von Heroin und Naloxon zur Drogensubstitution
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
WO2009051824A2 (en) * 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8486448B2 (en) 2007-12-17 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
CN102316857A (zh) 2008-12-16 2012-01-11 莱博法姆公司 防止误用的控释配方
US20100196436A1 (en) * 2009-01-30 2010-08-05 Gooberman Lance L Implants containing disulfiram and an anti-inflammatory agent
US8791093B2 (en) * 2009-05-29 2014-07-29 Lance L. Gooberman Pharmaceutical delivery systems for treatment of substance abuse and other addictions
WO2011112709A1 (en) * 2010-03-09 2011-09-15 Elan Pharma International Limited Alcohol resistant enteric pharmaceutical compositions
RU2476209C1 (ru) * 2012-02-29 2013-02-27 Станислав Анатольевич Кедик Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
BR112016002342A8 (pt) 2013-08-06 2018-01-23 Dong Kook Pharm Co Ltd microesfera entecavir, método para preparação de uma microesfera entecavir, e, composição farmacêutica
WO2016013993A1 (en) * 2014-07-25 2016-01-28 Imuneks Farma Llac Sanayi Ve Ticaret A.Ş. Stable preservative free ophthalmic formulations of opioid antagonists
MX2021004027A (es) 2018-10-15 2021-08-11 Chong Kun Dang Pharmaceutical Corp Composiciones de microparticulas inyectables de naltrexona de accion prolongada.
GR1009871B (el) * 2019-07-30 2020-11-12 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει μικροσφαιριδια ναλτρεξονης και μεθοδος παρασκευης αυτου
US20210059943A1 (en) * 2019-09-04 2021-03-04 Buffalo Pacific LLC Systems and methods addressing multiple aspects to provide a comprehensive recovery program for addictions, chronic conditions and diseases
CA3208374A1 (en) * 2021-03-09 2022-09-15 Ju Hee Kim Sustained formulation for prevention or treatment of autoimmune disease containing naltrexone and method using same
WO2023090922A1 (ko) * 2021-11-18 2023-05-25 (주)인벤티지랩 날트렉손을 포함하는 서방성 주사용 조성물 및 이의 제조 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4623588A (en) 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
US4568559A (en) 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
US4981696A (en) 1986-12-22 1991-01-01 E. I. Du Pont De Nemours And Company Polylactide compositions
DE3710175A1 (de) 1987-02-12 1988-08-25 Hoechst Ag Mehrteilige implantierbare arzneizubereitung mit langzeitwirkung
FR2618674B1 (fr) 1987-07-30 1990-06-15 Ire Celltarg Sa Microparticules comportant un polymere biodegradable controlant la liberation d'un principe actif antimalarique, compositions pharmaceutiques en comprenant et procede de preparation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
DE3734223A1 (de) * 1987-10-09 1989-04-20 Boehringer Ingelheim Kg Implantierbares, biologisch abbaubares wirkstofffreigabesystem
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US4902515A (en) 1988-04-28 1990-02-20 E. I. Dupont De Nemours And Company Polylactide compositions
EP0471036B2 (en) 1989-05-04 2004-06-23 Southern Research Institute Encapsulation process
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
CA2290788A1 (en) * 1997-05-20 1998-11-26 Suchitra Krishnan-Sarin Substance dependence treatment using opiate antagonists and serotonin compounds
JPH11269094A (ja) * 1998-01-16 1999-10-05 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途

Also Published As

Publication number Publication date
UA79921C2 (en) 2007-08-10
NZ515359A (en) 2002-10-25
EP1171132B1 (en) 2004-03-31
WO2000061147A1 (en) 2000-10-19
IL145802A0 (en) 2002-07-25
EA200101062A1 (ru) 2002-04-25
JP2002541202A (ja) 2002-12-03
PL196930B1 (pl) 2008-02-29
BR0009639A (pt) 2002-02-05
US6306425B1 (en) 2001-10-23
ES2218147T3 (es) 2004-11-16
DE60009477T2 (de) 2005-02-24
IL145802A (en) 2009-02-11
KR20020011975A (ko) 2002-02-09
NO20014896L (no) 2001-12-07
HK1047245A1 (en) 2003-02-14
HUP0200838A2 (hu) 2002-07-29
CZ20013636A3 (cs) 2002-03-13
AU780852B2 (en) 2005-04-21
PT1171132E (pt) 2004-07-30
JP2010031036A (ja) 2010-02-12
CA2369302C (en) 2007-09-25
DK1171132T3 (da) 2004-07-12
CA2369302A1 (en) 2000-10-19
KR100621261B1 (ko) 2006-09-13
JP4995371B2 (ja) 2012-08-08
CN1354664A (zh) 2002-06-19
CN1210031C (zh) 2005-07-13
AU4220300A (en) 2000-11-14
NO20014896D0 (no) 2001-10-08
EA004734B1 (ru) 2004-08-26
NO328647B1 (no) 2010-04-19
EP1171132A1 (en) 2002-01-16
HK1047245B (zh) 2006-03-03
MXPA01010185A (es) 2003-07-21
PL350548A1 (en) 2002-12-16
ATE262906T1 (de) 2004-04-15
DE60009477D1 (de) 2004-05-06
HUP0200838A3 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
TR200102880T2 (tr) Enjekte edilebilir naltrekson mikrokre bileçimleri ve bunlarìn eroin ve alkol tketiminin azaltìmì i‡in kullanìmì
TWI235068B (en) Sustained-release pharmaceutical composition
PE20010053A1 (es) Formulacion de amoxicilina y clavulanato de potasio
CY1108587T1 (el) Φαρμακευτικη συνθεση για τροποποιημενη απελευθερωση ενος ευαισθητοποιητη ινσουλινης και μετφορμινης
TR199801824T2 (tr) Aglomeratlar.
TR200101261T2 (tr) Uzun süreli salınımlı ranolazin formülasyonları.
HK1086475A1 (en) Controlled-release compositions
ATE286057T1 (de) Pharmazeutische zubereitungen enthaltend clavulansäure
FR2802933B1 (fr) Poly(acetal), sa preparation, composition anti-reflechissante le contenant, et dispositif a semi-conducteur utilisant cette composition
DE69703619T2 (de) Steroid-nitrit und nitrat-ester-verbindungen und ihre verwendung als antiphlogistische medikamente
AU9086801A (en) Detection of microsatellite instability and its use in diagnosis of tumors
TR200400187T2 (tr) Yeni oral formülasyon.
AR029509A1 (es) Una composicion farmaceutica en base a un compuesto de platino (iv) y el uso de dicho compuesto para preparar medicamentos antitumorales
BR0317708A (pt) Composto, composição farmacêutica, e, uso de um composto
TR200101337T2 (tr) Değiştirilmiş salımlı ensülin sensitizörü için farmasötik terkip ve kullanımı.
DE69219901T2 (de) Adenosinderivate, Verfahren zu deren Herstellung und pharmazeutische Mittel
DE69302829T2 (de) Bicyclische pyrimidinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate
BR0011261B1 (pt) composiÇço oral compreendendo perlita, e, uso de perlita.
TR200103237T2 (tr) İmidazodiazepin türevi
BR0110450A (pt) Uso de agonistas receptores d4 de dopamina seletivo para tratamento de disfunção sexual
DE69431123T2 (de) Pharmazeutische zusammensetzungen enthalten ceftriaxon und peneme
SE9701825D0 (sv) Anordning vid förbränning, inmatning och lagring av pulverformade bränslen
关闭 Bio-invasion Studies for National Ecological Security
UA86929C2 (ru) Композиция с контролируемым высвобождением
IT1278534B1 (it) Preparazioni farmaceutiche per uso veterinario contenenti amossicillina triidrato in forma di polvere solubile